Trial Profile
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 17 Oct 2023 Status changed from active, no longer recruiting to completed.
- 30 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 26 Jul 2022 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.